Pharmacokinetic Bioequivalence of ATI-0918 and DOXIL®/CAELYX® in Patients with Ovarian Cancer | BioAgilytix

Objective

To assess the pharmacokinetic (PK) bioequivalence of ATI-0918 (test product) and DOXIL®/CAELYX® (reference product).

Download Poster

Use of Cold Compounds and High Resolution Mass Spectrometry to Quickly Characterize Drug Uptake in Cryopreserved Human Hepatocytes

Pharmacokinetics of Subcutaneously-administered CBX129801, A Long-acting Synthetic C-Peptide in Patients with Type 1 Diabetes Mellitus